Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Immunity to Measles Virus in the Thai Population Age 18-30 Years and Predictive Factors

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2012 by Queen Saovabha Memorial Institute.
Recruitment status was:  Not yet recruiting
Information provided by (Responsible Party):
Jaruboot Angsanakul, Queen Saovabha Memorial Institute Identifier:
First received: May 16, 2012
Last updated: May 17, 2012
Last verified: May 2012

Prevalence of participants who have protective immunity to measles virus is less than ninety percent.

Predictor of adequate measles antibody levels include the following :

  • History of measles infection
  • History of complete measles primary immunization( 2 doses with at least 1 month interval after age of 9 months)
  • History of measles exposure

Predictor of inadequate measles antibody levels include the following :

  • Born outside Thailand
  • History of staying outside Thailand for long time in childhood
  • Living in the rural area for a long period in childhood
  • Fail to participate school system on time


Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Immunity to Measles Virus in the Thai Population Age 18-30 Years and Predictive Factors

Resource links provided by NLM:

Further study details as provided by Queen Saovabha Memorial Institute:

Biospecimen Retention:   Samples Without DNA
Each participant will be taken blood sample approximately 8 ml. The blood sample will be centrifuged and kept as serum. The serum will be kept under - 20 degree Celsius. Then, all serum will be tested by ELISA.

Estimated Enrollment: 550
Study Start Date: July 2012
Estimated Study Completion Date: March 2013
Estimated Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Adequate antimeales antibody levels
ELISA test OD > 0.1
Inadequate measles antibody levels
ELISA test OD < 0.1


Ages Eligible for Study:   18 Years to 30 Years   (Adult)
Genders Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Health Thai participant age 18-30 years old.

Inclusion Criteria:

  • Age 18-30 years old

Exclusion Criteria:

  • Last measles vaccination less than 10 years of age
  • Immunocompromised host including congenital immune defect, splenectomy or splenic dysfunction, history of suspect HIV exposure, taking immunosuppressant
  • Receiving blood or blood product within 3 months
  • Receiving others vaccinations or immunoglobulins or any medication that possibly decrease immune response
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01602094

Queen Saovabha Memorial Institute
Bangkok, Thailand, 10330
Sponsors and Collaborators
Queen Saovabha Memorial Institute
Principal Investigator: Jaruboot Angsanakul, M.D. Queen Saovabha Memorial Institute
  More Information

Additional Information:
Responsible Party: Jaruboot Angsanakul, Queen Saovabha Memorial Institute Identifier: NCT01602094     History of Changes
Other Study ID Numbers: TAI5501 
Study First Received: May 16, 2012
Last Updated: May 17, 2012
Health Authority: Thailand: Ministry of Public Health

Keywords provided by Queen Saovabha Memorial Institute:
Donor of National Blood Centre, The Thai Red Cross Society who age 18-30 years old
Measles antibody levels
Predictors of adequate measles antibody levels and inadequate measles antibody levels

Additional relevant MeSH terms:
Morbillivirus Infections
Paramyxoviridae Infections
Mononegavirales Infections
RNA Virus Infections
Virus Diseases
Immunologic Factors
Physiological Effects of Drugs processed this record on January 17, 2017